Article Versions Notes

Kitsunai H, Shinozaki Y, Furusawa S, Kitao N, Ito M, Kurihara H, Oba-Yamamoto C, Takeuchi J, Nakamura A, Takiyama Y, et al. The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study. Pharmaceuticals. 2025; 18(1):129. https://doi.org/10.3390/ph18010129

Kitsunai, Hiroya, Yuka Shinozaki, Sho Furusawa, Naoyuki Kitao, Miki Ito, Hiroyoshi Kurihara, Chiho Oba-Yamamoto, Jun Takeuchi, Akinobu Nakamura, Yumi Takiyama, and et al. 2025. "The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study" Pharmaceuticals 18, no. 1: 129. https://doi.org/10.3390/ph18010129

Kitsunai, H., Shinozaki, Y., Furusawa, S., Kitao, N., Ito, M., Kurihara, H., Oba-Yamamoto, C., Takeuchi, J., Nakamura, A., Takiyama, Y., & Nomoto, H. (2025). The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study. Pharmaceuticals, 18(1), 129. https://doi.org/10.3390/ph18010129